in vivo-jetRNA®+ is a lipid-based transfection reagent composed of preformed liposomes specifically developed for in vivo mRNA delivery.
Meet our team at booth#1017 during the Festival of Biologics 2023 in Basel, Switzerland on October 10th - 12th 2023. Don't miss the opportunity to check our poster presentation on Improving mAbs yield and quality through plasmid engineering.
Poster : Improving mAbs yield and quality through plasmid engineering
Recombinant monoclonal antibodies (rmAbs) will become part of the therapeutical arsenal for numerous pathologies, The generalization of their usage will be driven by faster development program and lower production costs, both criteria being directly dependent on the productivity of our bioprocesses. During the past decades impressive progresses have been made regarding the bioproduction equipment’s, cell models and purification processes. The improvement of the biomolecular components, that are the plasmids, has somewhat lagged behind such developments. With the booming of molecular technologies of DNA assembly methods, including the proprietary e-Zyvec® method from Polyplus®, we have new opportunities to explore the potential of plasmid engineering as another leverage to increase yield and quality of rmAbs bioproduction.
Discover Our Applications
Cell & Gene Therapy
Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types